Cemiplimab
Cemiplimab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Non-Small Cell Lung Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
2 项
已进入 III/IV 期
15 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- ETOP IBCSG Partners Foundation
- Regeneron Pharmaceuticals
- University of Oklahoma
- QuantumLeap Healthcare Collaborative
- Montefiore Medical Center
- University of Chicago
- Maastricht University Medical Center
- InSightec
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、澳大利亚、比利时、法国、Israel、意大利、荷兰、South Korea、西班牙、英国、加拿大、中国台湾
正在招募患者的 Cemiplimab 研究
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
I 期 / II 期招募中美国澳大利亚比利时法国NCT03564340Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
II 期招募中美国NCT07223541I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
II 期招募中美国NCT01042379Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
II 期招募中美国NCT06865339A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
II 期招募中美国NCT07603856Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
I 期 / II 期招募中比利时荷兰西班牙NCT04954599Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
III 期招募中美国加拿大South KoreaNCT05317858Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
II 期招募中美国NCT06860815Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer
不适用招募中加拿大NCT06743581Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma
I 期 / II 期招募中西班牙NCT07251413Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma
II 期招募中法国NCT07234058Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
II 期招募中美国加拿大South Korea中国台湾NCT06787612Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
II 期招募中法国NCT06656598Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab
II 期招募中德国NCT07387198Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
II 期招募中美国NCT06449313A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
I 期 / II 期招募中美国NCT03972657Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
I 期 / II 期招募中美国NCT06088771Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
II 期招募中西班牙NCT06887088Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
II 期招募中美国NCT06205836A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
III 期招募中美国加拿大NCT06246916XL092 and Cemiplimab in BRAF WT Thyroid Cancer
I 期招募中美国NCT06902376Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
II 期招募中美国NCT06463665A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
II 期招募中美国澳大利亚法国意大利NCT06769698Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
II 期招募中美国NCT06528769
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。